Avanafil Tablet
Product Images NDC 31722-441

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Avanafil (NDC 31722-441). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100mg-30slabel (100mg 30slabel)

Label for Avanafil 100 mg tablets by Camber Pharmaceuticals, Inc. The label states the product name and strength, packaging size of 30 tablets, and includes storage instructions and a U.S. contact number. It mentions the product is manufactured by Hetero Labs Limited, India, and displays a barcode, NDC number 31722-441-30, and a blank pink area labeled '43 x 26 mm Un Varnish Area'.*

FDA Label Image

200mg-30slabel (200mg 30slabel)

Avanafil 200 mg tablets label showing it contains 30 oral tablets. The label includes the Camber Pharmaceuticals, Inc. logo, a barcode, storage instructions, and manufacturer details listing Hetero Labs Limited in India. It notes the product is prescription only and provides a U.S. contact number.*

FDA Label Image

50mg-30slabel (50mg 30slabel)

Avanafil Tablets 50 mg oral tablet label by Camber Pharmaceuticals, Inc. The label states 30 tablets per package and includes a barcode, lot number, storage instructions, and manufacturer details including Hetero Labs Limited in India. It is marked Rx only with dosage strength prominently shown.*

FDA Label Image

Avanafil-structure (Avanafil Structure)

Chemical structure diagram of Avanafil, illustrating the molecular framework of the active ingredient used in the oral tablet dosage form manufactured by Camber Pharmaceuticals, Inc.*

FDA Label Image

Camber-logo (Camber Logo)

FDA Label Image

Camber-logo2 (Camber Logo2)

FDA Label Image

Figure-1 (Figure 1)

A line graph comparing systolic blood pressure changes (mmHg) over time (hours) after dosing with Avanafil 200 mg versus placebo. The vertical axis shows systolic blood pressure, and the horizontal axis shows time post dose from 0 to 3 hours. Data series for Avanafil 200 mg and placebo are displayed with distinct markers.*

FDA Label Image

Figure-2 (Figure 2)

A line graph comparing the effect of Avanafil 200 mg and placebo on a measurement in mmHg over time from 0 to 6 hours post dosing. The y-axis shows a range from -10.0 to 20.0 mmHg. Data points for Avanafil 200 mg and placebo are connected with lines and include error bars representing variability.*

FDA Label Image

Figure-3 (Figure 3)

A line graph comparing the change in mmHg over time (hours from dosing) between Avanafil 200 mg and placebo groups. The x-axis represents hours from dosing (0 to 6 hours), and the y-axis represents mmHg changes ranging from -10 to 20. Two lines with error bars show trends for Avanafil 200 mg and placebo groups across the 6-hour period.*

FDA Label Image

Figure-4 (Figure 4)

A line graph depicting plasma concentration (ng/mL) of Avanafil over time (hours) for 50 mg and 200 mg oral tablet doses. The 200 mg dose shows higher concentration peaks and a decline over 24 hours, while the 50 mg dose shows lower concentration values with similar timing. Error bars indicate variability at each time point.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.